Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus

Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus

The human infectious disease COVID-19 caused by the SARS-CoV-2 virus has become a major threat to global public health. Developing a vaccine is the preferred prophylactic response to epidemics and pandemics. However, for individuals who have contracted the disease, the rapid design of antibodies tha...

Full description

Bibliographic Details
Main Authors: Nancy E. Hernandez, Wojciech Jankowski, Rahel Frick, Simon P. Kelow, Joseph H. Lubin, Vijaya Simhadri, Jared Adolf-Bryfogle, Sagar D. Khare, Roland L. Dunbrack, Jr., Jeffrey J. Gray, Zuben E. Sauna
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Heliyon
Subjects:
Protein engineering
Coronavirus Disease 2019
Computational antibody design
Monoclonal antibody therapeutics
Diagnostic
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023022399

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023022399

Similar Items